About Erasca Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.erasca.com/
Frequently Asked Questions
What is the 52-week range for ERAS?
The 52-week high is $24.28 and the 52-week low is $2.1.
What is the P/E ratio for ERAS?
The P/E ratio data is currently unavailable.
What is the dividend yield for ERAS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -80.43%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.25.
Analyst Recommendation Trends
Wall Street analyst consensus for ERAS over the last few months:
Latest ERAS News
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset MELBOURNE, Australia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a comparative analysis of l
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS TherapiesMELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today issued a co
Erasca, Inc. (ERAS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Erasca, Inc. (ERAS) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:05 PM EDTCompany ParticipantsJonathan Lim - Co-Founder,...
Wondering what's happening in today's after-hours session?
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 trial Poster presentation to share nonclinical combination data of ERAS-0015 and ERAS-4001 demonstrating synergy in KRAS G12X-driven models SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference being held at the New York Marriott Marquis in New York, NY. Management will participate in a fireside chat on Tuesday, September 15, 2026, at 1:05 pm Easte
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage
On August 24, Erasca (NASDAQ:ERAS) announced that the FDA had granted Fast Track Designation to ERAS-0015, its oral pan-RAS molecular glue, for patients with metastatic pancreatic adenocarcinoma. The designation gives Erasca more frequent contact with regulators and, if the drug keeps clearing bars, a shot at accelerated approval, priority review, and rolling review. For a […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-10 | Fuchs Charles S. | +1,300,000 | - | - |
| 2026-04-01 | Garner Ebun | -80,000 | - | - |
| 2026-04-01 | Garner Ebun | -80,000 | $16.4 | $1,312,000 |
| 2026-04-01 | Garner Ebun | +80,000 | $1.7 | $136,000 |
| 2026-03-04 | Morris Shannon | -20,000 | $15.038 | $300,760 |
| 2026-03-04 | Morris Shannon | +20,000 | $1.7 | $34,000 |
| 2026-01-29 | Chacko David M. | +640,000 | - | - |
| 2026-01-29 | Morris Shannon | +625,000 | - | - |
| 2026-01-29 | Varney Michael David | +96,000 | - | - |
| 2026-01-29 | Garner Ebun | +560,000 | - | - |
| 2026-01-29 | Lim Jonathan E | +2,000,000 | - | - |
| 2026-01-07 | Garner Ebun | -120,000 | $5.5901 | $670,812 |
| 2026-01-07 | Garner Ebun | +120,000 | $1.7 | $204,000 |
| 2026-01-01 | Bristol James Arthur | +37,762 | - | - |
| 2026-01-01 | Start Valerie Denise Harding | +24,306 | - | - |
| 2026-01-01 | Multani Pratik S | +19,532 | - | - |
| 2026-01-01 | Casdin Alexander W. | +23,872 | - | - |
| 2026-01-01 | LIU JEAN I | +20,617 | - | - |
| 2025-12-15 | Chacko David M. | +17,793 | $1.1943 | $21,250 |
| 2025-12-15 | Garner Ebun | +3,902 | $1.1943 | $4,660 |